Evolus, Inc. Signs Licensing Deal With Daewoong Pharmaceutical Co.

Represented Evolus, Inc., a U.S. biotech venture, in its exclusive licensing deal with Daewoong Pharmaceutical Co., a major South Korean drugmaker, in Daewoong's bid to sell its botox products in the U.S. and European markets beginning as early as 2016.

Evolus, Inc. manufactures clinical neurotoxins used in cosmetic surgery.